The hyaluronidase inhibiting property of blood serum has been found to be increased in such diverse clinical states as infectious diseases of bacterial and viral origin (1) (2) (3) (4) , neoplastic disease (5, 6) , and the postpartum state in women (7) as well as in several of the so-called "collagen diseases" of unknown etiology, notably rheumatic fever (8, 9) , disseminated lupus erythematosis (2) and dermatomyositis (2) . Intensive studies to determine the anatomical site of origin and to understand better the nature of this substance have been undertaken, and are still under way in this laboratory.
Clear evidence of the site of origin of the inhibiting substance is lacking. Wattenberg and Glick (10) , in an analysis of a wide variety of tissues from the rabbit, found it in none of the material studied. In the course of their investigations they noted that certain hemoglobin derivatives and steroids possessed inhibitory properties; extending their observations, they noted that many similar chemical compounds also produced inhibition, but that such compounds were uniformly heat stable and not, as is the serum inhibitor, heat labile. The interest in these investigations, as well as in the current one, has been in the nonspecific inhibitor which will act on the enzyme regardless of its source, rather than the specific antibody inhibitors that develop when hyaluronidase is used as an antigen (11) . It has also been found that the inhibitor migrates with 'albumin in an electrophoretic field (12, 13 
MATERIALS AND METHODS
The technic of the preparation of materials, the viscosimetric assay method, and the method of calculation of results follow the procedure as described by Glick and Gollan (1) and modified by Wattenberg and Glick (10) . The hyaluronic acid employed was obtained from human umbilical cords, and the hyaluronidase from bull testes. The assays were carried out on 0.02 ml. samples of serum, and when repeated analyses were to be run on the same patient, the material was stored at -250 C. until all could be run at the same time, thus eliminating possible variations between different batches of enzyme and substrate. In most instances the patient was used as his own control, via comparisons in serial determinations. The degree of inhibition has been expressed as per cent inhibition, and in a large series of normal humans the mean was found to be 21.5 + 0.7. This range of normal values was found to hold for an age group well beyond that covered by the patients in the group studied in this investigation.
Concomitant determinations were available of routine laboratory studies of blood and urine, and in most instances serial values of erythrocyte sedimentation rate, total and fractional serum protein, serum bilirubin (both one minute and total), cephalin-cholesterol flocculation, thymol turbidity, bromsulfalein retention and urine urobilinogen, serum alkaline phosphatase activity, and cholesterol and cholesterol esters. Routine control sera from normal individuals were run at frequent intervals throughout the entire investigation; these were found to fall within 1 per cent of the previously established normal average value. Serial determinations of inhibitor were made during periods believed to represent changes in the clinical course of the disease process, though in some liver disease as grouped in Table I ; no predictable pattern was found to obtain in any one group that might serve to distinguish it from the other groups of liver disease. There was, however, a rather close correlation of the level of the inhibitor with the clinical course of the disease in all cases observed, in that the highest inhibitor levels were found when the disease process was clinically most severe, with a decline in the level as the disease remitted as gauged by the bedside examination. Similarly, in other papers of this series, a decline from previously high values has been reported in the recovery stage of acute poliomyelitis (1), and in a wide variety of infectious diseases (3). The clinical and laboratory course of a typical case from the material studied is shown in Table II .
An exception to this direct correlation was observed in several cases of hepatic coma, in which as the extreme terminal phase of hepatic failure was reached, distinctly subnormal values obtained; this was found in patients who had shown abnormally elevated values prior to their terminal liver failure.
In the light of the finding by Wattenberg and Glick (10) of an inhibitor effect inherent in several bile constituents, the possibility was entertained that the elevated inhibitor values might be due to an additive effect of these constituents, in cases where the serum levels of bile products were elevated. This was disproved by the finding of a 2. A definite correlation was found between serum hyaluronidase inhibitor and both clinical course and several laboratory tests of liver function, i.e., alkaline phosphatase, bilirubin, bromsulfalein, and total cholesterol. Several other tests showed no significant correlation. Elevated values were noted when the disease process was at its height, and these values diminished as the patients recovered.
3. An exception to this correlation was noted in several cases of severe hepatic coma; here previously elevated values became subnormal in the very terminal stages of hepatic failure. This finding has suggested the interesting speculation that the integrity of a certain amount of hepatic function is necessary for the development of both normal and elevated levels of serum inhibitor.
